読み込み中
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
最新データ
$3.85
+$0.04 · +1.05%
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
23
割高
センチメント
47
まちまち
リスク
59
やや高いリスク
モメンタム
39
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$21.00
上昇余地（445.45%）価格履歴は利用できません
最高：$29.00平均：$21.00最低：$13.00評価サンプルは4件と限定的です
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
